Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease

NCT ID: NCT06925594

Last Updated: 2025-04-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 228 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-20
• Study Completion Date: 2028-06-28

Brief Summary

The purpose of this study is to evaluate the efficacy of human TH-SC01 cell injection for the treatment of perianal fistulas in Crohn's Disease over 24 weeks.

Conditions

Crohn's Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Treatment Arm

120 million cells administered by intralesional injection.

Group Type: EXPERIMENTAL

Human TH-SC01 cell injection

Intervention Type: OTHER

Human TH-SC01 cell injection is a cell suspension in aseptic buffered solution containing human expanded umbilical cord-derived stem cells of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.

Placebo-control group

24 mL saline solution by intralesional injection

Group Type: PLACEBO_COMPARATOR

Saline solution

Intervention Type: OTHER

Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.

Interventions

Human TH-SC01 cell injection

Human TH-SC01 cell injection is a cell suspension in aseptic buffered solution containing human expanded umbilical cord-derived stem cells of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.

Intervention Type: OTHER

Saline solution

Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent

2. Subjects with Crohn's disease diagnosed at least 6 months earlier according to the Chinese Consensus Opinion on the Diagnosis and Treatment of Inflammatory Bowel Diseases (Beijing, 2018)

3. Subjects with active perianal fistula and non active luminal CD defined by a CDAI ≤ 200.

4. Presence of perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI.

5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.

6. American Society of Anesthesiologists (ASA) physical status classification of grade I to grade II.

7. All subjects and their partners were not planning to have a child from screening to the end of the trial and agreed to use effective non-drug contraception during the trial.

Exclusion Criteria

1. Subjects allergic to human serum albumin, human platelet lysate, gentamicin sulfate, anesthetic drugs or MRI contrast agents.

2. Subjects with active infection evaluated by the investigator

3. Subjects with active Crohn's disease before drug administration or have not completed the induction-phase treatment.

4. Subjects with abscess or collections >2 cm.

5. Rectal and/or anal stenosis , if this means a limitation for any surgical procedure

6. Subjects with concurrent active proctitis.

7. Subjects with other fistulas such as rectum/anal canal-vaginal fistulas or rectum-bladder fistulas.

8. Patients have undergone a diverting stoma operation in the past, except for patients have completed stoma closure at least one month before drug administration.

9. Patients plan to undergo surgery in the perianal area during the trial period due to other diseases other than anal fistula.

10. Subjects with abnormal laboratory results: liver function: total bilirubin >=1.5 × ULN, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >=2 × ULN; renal function: creatinine clearance below 60 mL/minute calculated using Cockcroft-Gault formula or by serum creatinine >=1.5 × upper limit of normal (ULN).

11. Serum virology test (HBeAg, HCV antibody, HIV antibody, Treponema pallidum antibody) positive.

12. Subjects with malignant tumors or a history of malignant tumors.

13. Subjects with congenital or acquired immunodeficiency.

14. Contraindication to MRI scan

15. Current or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.

16. Subjects received stem cell treatment within two years prior to screening.

17. Patient with ongoing steroid treatment or treated with steroids in the last 4 weeks.

18. Patient undergone major surgical operations (such as orthopedic surgery, abdominal surgery) within one month before drug administration, or Patient plan to receive surgeries during the study period (except for the surgeries required by the procedures of this trial).

19. Patients with a history of drug abuse or alcoholism (Criteria for alcoholism: having a long-term drinking history of more than 5 years, with the amount of ethanol equivalent to ≥40g/d for men and ≥20g/d for women, or having a history of heavy drinking within 2 weeks, with the amount of ethanol equivalent to >80g/d. The conversion formula for the amount of ethanol (g) = the amount of alcohol consumed (ml) × the ethanol content (%) × 0.8).

20. Pregnant or lactating women.

21. Patients with a history of diverting ostomy, except those who have undergone stoma reversal at least 1 month prior to drug administration.

22. Other diseases or conditions that the investigator deems inappropriate for participating in this clinical trial, such as poor subject compliance and the expectation of being unable to complete follow-up and evaluation.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Nanjing, Jiangsu, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jueyu Xia, Master

Role: CONTACT

xiajueyu@topcelbio.com

025-52700103

Facility Contacts

Jueyu Xia, Master

Role: primary

xiajueyu@topcelbio.com

025-52700103

Other Identifiers

TH-SC01-CD-Ⅲ-01

Identifier Type: -

Identifier Source: org_study_id